Infinataâ€™s BioPharm Insight to Host Expert Panel Discussing the Multiple Sclerosis Drugs Landscape via Complimentary Online Webinar on September 28, 2011
Biopharma intelligence provider will also moderate live panel on funding biopharma innovation at Prix Galien USA on September 27 in NYC.
Norwood, MA (PRWEB) September 21, 2011
Over the following week, BioPharm Insight Global Editor Kimberly Ha will host two important and educational expert panels Ã¢“ one live, one online Ã¢“ focused on funding biopharma innovation and the Multiple Sclerosis drug development landscape, respectively.
September 27, 2011 Ã¢“ At the prestigious Prix Galien USA Forum in NYC, Ms. Ha will moderate a premier roundtable exploring new trends in the healthcare M&A landscape to fund innovation. Featured speakers include principals from the Miller Tabak Health Care Transformation Fund, Ferghana Partners, Proskauer, OrbiMed Advisors and the Keffi Group. To learn more about the forum, visit http://forum.galienfoundation.org. Current BioPharm Insight clients receive complimentary admission into the event, while newsletter subscribers receive a 30% discount. Contact Kris Sarajian, Marketing Director at Infinata, at ksarajian(at)infinata(dot)com for details.
September 28, 2011 Ã¢“ Join colleagues and industry executives for an interactive online interview on Multiple Sclerosis drugs with key opinion leaders Dr. Daniel Kantor (Medical Director, Neurologique) and Dr. Samuel Hunter (President, Advanced Neurosciences Institute). Hosted by Ms. Ha, the informational agenda will cover topics including an overview of MS drugs in development such as BG-12 (Biogen) and Campath (Sanofi), emerging trends in MS treatments, the real-world response to Ampyra (Acorda) and BiogenÃ¢s JC virus assay for Tysabri Ã¢“ as well as questions posed by attendees. The one-hour webinar begins at 12:00pm ET and is free to attend. To reserve your space, register at https://www2.gotomeeting.com/register/535560882.
Infinata provides personalized technology solutions to help clients turn information into insight. Featuring exclusive biopharmaceutical intelligence and business development tools such as BioPharm InsightÃ¢“¢ and BioPharm ClinicalÃ¢“¢, Infinata helps biopharma companies, CROs, service providers and financial markets firms understand and become active participants in their global industry. Infinata is a part of the Financial Times Group, a division of Pearson PLC (NYSE:PSO). To learn more, visit http://www.infinata.com or http://www.biopharminsight.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/9/prweb8800247.htm